Protocol Ledger

NCT04068103 · Phase II/III · ACTIVE NOT RECRUITING

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Interventional Phase II/III clinical trial protocol NCT04068103 sponsored by NRG Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-12-16 Enrollment: 635 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04068103
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)635 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04068103
Protocol FieldVerified Registry Value
NCT IdentifierNCT04068103
Consolidated Lead SponsorNRG Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment635 participants (ACTUAL)
Registered Start Date2019-12-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI